Cannabidiol Oil Cbd Oil MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Distribution ChannelBy FormulationBy End Use

Cannabidiol (CBD) oil is a cannabinoid extract derived from hemp or marijuana plants, sold as a standalone tincture or as an input ingredient blended into pharmaceuticals, food and beverage products, cosmetics, and other consumer formats. Buyers span individual consumers purchasing wellness, sleep and pain-relief products directly, alongside formulators and manufacturers who purchase bulk or white-label CBD oil to incorporate into their own branded goods, and healthcare or veterinary practitioners who recommend or dispense CBD-based products to patients and animals.

Between 2025 and 2034 the global cannabidiol oil cbd oil market moves from USD 10.2 billion to USD 30.55 billion, compounding at 12.81% a year. Fifteen years are covered in all, taking in USD 3.8 billion in 2020, USD 8.85 billion in 2024, USD 11.65 billion in 2026 and USD 19.25 billion in 2030.

72% of 2025 revenue sits in Hemp-derived, worth USD 7.34 billion and rising to USD 20.07 billion at 65.7% by 2034, the largest type line in both years. Growth is fastest in Marijuana-derived at 16.24% and slowest in Hemp-derived at 11.66%. Share moves toward Marijuana-derived and away from Hemp-derived and Others, though no line shrinks in revenue terms.

The application split puts Cosmetics first, at USD 2.04 billion and 20% of revenue in 2025, rising to USD 7.03 billion and 23% in 2034. Pharmaceuticals grows faster at 15.15% against 14.74%, moving from 16% of revenue to 19% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

Geographically, 46% of 2025 revenue sits in North America (USD 4.69 billion rising to USD 12.92 billion) ahead of Europe at 27% and USD 2.75 billion. Middle East and Africa is smallest, at 4%. Europe and Asia Pacific gain share across the period, so growth is not distributed evenly between regions.

Coverage extends to five regions, three type lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• The global cannabidiol oil cbd oil market moves from USD 3.8 billion in 2020 to USD 10.2 billion in 2025 and USD 30.55 billion by 2034, the forecast period compounding at 12.81% a year.
• The largest line by type is Hemp-derived, worth USD 7.34 billion and 72% of revenue in 2025, rising to USD 20.07 billion and 65.7% by 2034.
• At 16.24%, Marijuana-derived grows faster than any other type line, moving from USD 2.04 billion and 20% of revenue in 2025 to USD 8.03 billion and 26.3% in 2034.
• Against a base case of USD 30.55 billion in 2034, the study also reports a bear case at USD 26.88 billion and a bull case at USD 34.22 billion, with the assumptions behind each set out separately.
• North America holds 46% of global revenue in 2025 at USD 4.69 billion, the largest of the five regions tracked, and reaches USD 12.92 billion by 2034.
• 85.07% of North America's base-year revenue comes from the United States alone: USD 3.99 billion in 2025, rising to USD 10.98 billion by 2034, which is why it is that region's worked example.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 12.81% compounding underneath both.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; the question is which takes the larger part of the growth.

Composition shifts on the type axis. Between 2026 and 2034, 16.24% growth in Marijuana-derived against 11.66% in Hemp-derived pulls the type mix apart. Shares follow: 20% to 26.3% for Marijuana-derived, 72% to 65.7% for Hemp-derived. The revenue figures behind that are USD 2.04 billion to USD 8.03 billion and USD 7.34 billion to USD 20.07 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Regional weight shifts toward Europe and Asia Pacific. Europe moves from 27% of revenue in 2025 to 27.9% in 2034, worth USD 2.75 billion rising to USD 8.52 billion; Asia Pacific moves from 17% of revenue in 2025 to 19.8% in 2034, worth USD 1.73 billion rising to USD 6.05 billion. Share moves off the others in turn: North America at 46% moving to 42.3%, Latin America at 6% moving to 6%, Middle East and Africa at 4% moving to 4%, each still growing in revenue terms. That makes the regional split worth reading rather than scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

A continuation, not an inflection. The market moves through USD 3.8 billion in 2020, USD 8.85 billion in 2024, USD 10.2 billion in 2025, USD 11.65 billion in 2026, USD 19.25 billion in 2030 and USD 30.55 billion in 2034. There is no discontinuity to time, and 12.81% forecast growth against 21.83% historical means the trend continues rather than turns. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Growth is concentrated in Marijuana-derived

Growth in the global cannabidiol oil cbd oil market comes from three measurable sources over 2026-2034: the market's own compounding at 12.81%, the share gained by faster-growing type lines, and expansion in the regions taking a larger part of global revenue.

Downside case: USD 26.88 billion rather than USD 30.55 billion by 2034

Where the forecast could be beaten

One type line carries the market

In North America, 46% of global revenue puts 2025 at USD 4.69 billion with USD 12.92 billion projected for 2034. It is a dominant region on this axis, first by revenue throughout the period.

42.3% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

The type mix reported at global level applies here, with Hemp-derived the largest line at 72% of 2025 revenue and Marijuana-derived the fastest-growing at 16.24%. Per-axis and per-country detail for North America sits in the full report.

85.07% of North America's base-year revenue comes from the United States; USD 3.99 billion, rising to USD 10.98 billion by 2034. Carrying 85.07% of the region in the base year, it sets North America's direction rather than contributing to it. Set against USD 4.69 billion and USD 12.92 billion for the region, it is why this market rather than a smaller one is the one reported in full.

the United States buys along the same lines as the market globally; Hemp-derived first at 72% of 2025 revenue and 65.7% in 2034, Marijuana-derived fastest at 16.24% on a share moving from 20% to 26.3%. With 85.07% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for the United States is reported separately in the full report.

FDA regulates CBD oil. Under the Federal Food, Drug, and Cosmetic Act, CBD is not permitted as a dietary supplement ingredient or food additive at the federal level, though the agency has signaled intent to explore a regulatory pathway. Hemp-derived CBD is legal for cultivation under the Agriculture Improvement Act, but products marketed for ingestion face an unresolved patchwork of state-level rules covering labelling, potency claims, and testing. Suppliers must avoid unapproved therapeutic claims, since only one CBD-based drug has received FDA approval as a prescription medicine, and other CBD products cannot claim to treat, cure, or prevent disease. State agencies often require certificates of analysis confirming cannabinoid content and contaminant screening.

Competition in the United States runs between the suppliers this study tracks: Aphria Inc., Folium Biosciences, Freedom Leaf, Inc., Green Roads of Florida, LLC, Charlotte's Web Holdings, Inc., ENDOCA, CBD American Shaman, CV Sciences, Inc., Medical Marijuana, Inc., Canopy Growth Corporation, Aurora Cannabis, MedMen Enterprises Inc., Curaleaf Holdings, Inc., Kazmira LLC, HempLife Today, Pharmahemp, Whistler Medical Marijuana Corporation, Absolute Terps, NuLeaf Naturals and Emblem Cannabis. Two different problems sit on the same axis: holding Hemp-derived at 72% of 2025 revenue, and taking Marijuana-derived while it grows at 16.24%. Per-company positioning and share at country level are in the full report only.

Canada is sized at USD 0.7 billion in 2025, rising to USD 1.94 billion by 2034; 6.86% of global revenue and 14.93% of North America. It is reported separately from the United States across every segmentation axis in the full report.

27% of the global cannabidiol oil cbd oil market sits in Europe in 2025, worth USD 2.75 billion and reaches USD 8.52 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.

27.9% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 12.81%; the revenue added here is disproportionate to where the region started.

Within the region the type split tracks the global one; 72% of 2025 revenue in Hemp-derived, fastest growth of 16.24% in Marijuana-derived. The full report breaks Europe out along every axis and by country.

USD 0.96 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 2.98 billion by 2034. At 34.91% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. The region itself runs USD 2.75 billion to USD 8.52 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Germany follows the type mix reported at global level: Hemp-derived is the largest line at 72% of 2025 revenue, moving to 65.7% by 2034, while Marijuana-derived grows fastest at 16.24% and takes its share from 20% to 26.3%. Because the country carries 34.91% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Germany carries its own type breakdown in the full report.

In Germany, CBD oil intended for ingestion falls under the EU Novel Food framework, administered nationally by the Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, since cannabidiol extracts require pre-market safety authorization before sale. Products applied topically must instead comply with the EU Cosmetics Regulation, while formulations carrying therapeutic claims fall under medicinal product rules enforced by the Bundesinstitut für Arzneimittel und Medizinprodukte. Suppliers must keep THC content below permitted thresholds under narcotics law, provide accurate ingredient and cannabinoid-content labelling, and avoid unauthorized health claims under EU food information rules. Import and distribution require documentation demonstrating compliance with novel food and controlled-substance provisions before goods can reach retail or pharmacy channels.

The suppliers tracked in this study (Aphria Inc., Folium Biosciences, Freedom Leaf, Inc., Green Roads of Florida, LLC, Charlotte's Web Holdings, Inc., ENDOCA, CBD American Shaman, CV Sciences, Inc., Medical Marijuana, Inc., Canopy Growth Corporation, Aurora Cannabis, MedMen Enterprises Inc., Curaleaf Holdings, Inc., Kazmira LLC, HempLife Today, Pharmahemp, Whistler Medical Marijuana Corporation, Absolute Terps, NuLeaf Naturals and Emblem Cannabis) compete in Germany across the type lines above. The commercially relevant division is 72% of 2025 revenue in Hemp-derived, where the volume is, against 16.24% growth in Marijuana-derived, where share moves.

The United Kingdom is sized at USD 0.77 billion in 2025, rising to USD 2.39 billion by 2034; 7.55% of global revenue and 28% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Within Europe, France accounts for 20% of regional revenue and 5.39% of the global total, worth USD 0.55 billion in 2025 and USD 1.7 billion by 2034.

17% of the global cannabidiol oil cbd oil market sits in Asia Pacific in 2025, worth USD 1.73 billion and reaches USD 6.05 billion by 2034. It is a mid-sized region on this axis, third by revenue throughout the period.

By 2034 the share has moved up to 19.8%, at a pace above the 12.81% global rate, which is what makes this region worth reading separately rather than scaling from the total.

Within the region the type split tracks the global one; 72% of 2025 revenue in Hemp-derived, fastest growth of 16.24% in Marijuana-derived. Per-axis and per-country detail for Asia Pacific sits in the full report.

USD 0.59 billion of Asia Pacific's 2025 revenue is generated in Australia, the region's largest market, reaching USD 2.06 billion by 2034. At 34.1% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. The region itself runs USD 1.73 billion to USD 6.05 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Hemp-derived at 72% of 2025 revenue, easing to 65.7% by 2034, and the fastest is Marijuana-derived at 16.24%, from 20% to 26.3%. With 34.1% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Australia by type separately.

The Therapeutic Goods Administration regulates CBD oil in Australia, classifying low-dose formulations as pharmacist-only medicines available without prescription, while higher-strength or therapeutic CBD products remain prescription-only under the Poisons Standard scheduling framework. Suppliers must secure entry onto the Australian Register of Therapeutic Goods, or supply unapproved products only through the Special Access Scheme or via an Authorised Prescriber pathway. Labelling must meet the therapeutic goods labelling order requirements, including accurate cannabinoid disclosure and warning statements. Manufacturers must demonstrate compliance with Good Manufacturing Practice standards, and advertising of therapeutic claims directly to consumers is tightly restricted under the Therapeutic Goods Advertising Code.

In Australia the field is Aphria Inc., Folium Biosciences, Freedom Leaf, Inc., Green Roads of Florida, LLC, Charlotte's Web Holdings, Inc., ENDOCA, CBD American Shaman, CV Sciences, Inc., Medical Marijuana, Inc., Canopy Growth Corporation, Aurora Cannabis, MedMen Enterprises Inc., Curaleaf Holdings, Inc., Kazmira LLC, HempLife Today, Pharmahemp, Whistler Medical Marijuana Corporation, Absolute Terps, NuLeaf Naturals and Emblem Cannabis. Volume sits in Hemp-derived at 72% of 2025 revenue; movement sits in Marijuana-derived at 16.24% growth.

Japan is sized at USD 0.52 billion in 2025, rising to USD 1.82 billion by 2034; 5.1% of global revenue and 30.06% of Asia Pacific. It is reported separately from Australia across every segmentation axis in the full report.

3.04% of global revenue is generated in South Korea; USD 0.31 billion in 2025, reaching USD 1.09 billion in 2034, and 17.92% of Asia Pacific.

6% of the global cannabidiol oil cbd oil market sits in Latin America in 2025, worth USD 0.61 billion rising to USD 1.83 billion in 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

Share settles at 6% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

Hemp-derived leads here as it does globally, at 72% of 2025 revenue, and Marijuana-derived again grows fastest at 16.24%. The full report breaks Latin America out along every axis and by country.

Brazil is the largest market within Latin America, generating USD 0.27 billion in 2025 and projected to reach USD 0.82 billion by 2034. At 44.26% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Set against USD 0.61 billion and USD 1.83 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Composition here matches the global split: the largest line is Hemp-derived at 72% of 2025 revenue, easing to 65.7% by 2034, and the fastest is Marijuana-derived at 16.24%, from 20% to 26.3%. Its 44.26% weight in Latin America means those movements carry straight into the regional totals. Brazil carries its own type breakdown in the full report.

In Brazil, CBD oil is regulated by Agência Nacional de Vigilância Sanitária, which classifies cannabidiol-based products as medicines requiring sanitary registration, or, for a more limited category, prior notification for lower-concentration formulations. Suppliers must demonstrate manufacturing quality, product safety, and consistent cannabinoid content through documentation submitted to the agency, and imported products require its authorization as well. Labelling must disclose composition, dosage instructions, and warnings, and marketing therapeutic claims without registration is prohibited. Distribution is restricted to authorized pharmacies or licensed retailers rather than general retail channels, reflecting the classification of these products as controlled therapeutic goods rather than conventional wellness items.

Competition in Brazil runs between the suppliers this study tracks: Aphria Inc., Folium Biosciences, Freedom Leaf, Inc., Green Roads of Florida, LLC, Charlotte's Web Holdings, Inc., ENDOCA, CBD American Shaman, CV Sciences, Inc., Medical Marijuana, Inc., Canopy Growth Corporation, Aurora Cannabis, MedMen Enterprises Inc., Curaleaf Holdings, Inc., Kazmira LLC, HempLife Today, Pharmahemp, Whistler Medical Marijuana Corporation, Absolute Terps, NuLeaf Naturals and Emblem Cannabis. The commercially relevant division is 72% of 2025 revenue in Hemp-derived, where the volume is, against 16.24% growth in Marijuana-derived, where share moves.

Mexico is sized at USD 0.21 billion in 2025, rising to USD 0.64 billion by 2034; 2.06% of global revenue and 34.43% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

USD 0.42 billion of 2025 revenue is generated in Middle East and Africa, 4% of the global cannabidiol oil cbd oil market with USD 1.23 billion projected for 2034. Among the five regions it ranks fifth by revenue in both years.

4% of global revenue sits here in 2034, below the 2025 level, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Hemp-derived largest at 72% of 2025 revenue, Marijuana-derived fastest at 16.24%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

The largest single market in Middle East and Africa is South Africa, at USD 0.17 billion in 2025 and USD 0.49 billion in 2034. It accounts for 40.48% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.42 billion in 2025 and USD 1.23 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Hemp-derived at 72% of 2025 revenue, easing to 65.7% by 2034, and the fastest is Marijuana-derived at 16.24%, from 20% to 26.3%. Since 40.48% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. South Africa carries its own type breakdown in the full report.

The South African Health Products Regulatory Authority oversees CBD oil, having moved low-concentration, over-the-counter formulations out of strict narcotic scheduling under the Medicines and Related Substances Act, provided they meet defined quality and exemption conditions, while higher-concentration or therapeutic-claim products remain regulated as scheduled medicines requiring registration. Suppliers must comply with the exemption criteria covering dosage guidance, manufacturing quality, and accurate labelling that discloses cannabinoid content and safety warnings. Products making medicinal claims require full registration supported by safety and efficacy evidence. General foodstuffs and cosmetics rules from the Department of Health apply where CBD is incorporated into non-therapeutic consumer goods, adding further labelling and safety obligations.

The suppliers tracked in this study (Aphria Inc., Folium Biosciences, Freedom Leaf, Inc., Green Roads of Florida, LLC, Charlotte's Web Holdings, Inc., ENDOCA, CBD American Shaman, CV Sciences, Inc., Medical Marijuana, Inc., Canopy Growth Corporation, Aurora Cannabis, MedMen Enterprises Inc., Curaleaf Holdings, Inc., Kazmira LLC, HempLife Today, Pharmahemp, Whistler Medical Marijuana Corporation, Absolute Terps, NuLeaf Naturals and Emblem Cannabis) compete in South Africa across the type lines above. Volume sits in Hemp-derived at 72% of 2025 revenue; movement sits in Marijuana-derived at 16.24% growth.

Within Middle East and Africa, the United Arab Emirates accounts for 35.71% of regional revenue and 1.47% of the global total, worth USD 0.15 billion in 2025 and USD 0.43 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Distribution Channel, Formulation, End Use, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.